Compare RPC & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RPC | CMPX |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | United States | United States |
| Employees | 267 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 932.7M | 927.5M |
| IPO Year | N/A | 2020 |
| Metric | RPC | CMPX |
|---|---|---|
| Price | $6.90 | $5.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $11.00 | ★ $14.43 |
| AVG Volume (30 Days) | 941.0K | ★ 1.7M |
| Earning Date | 05-08-2026 | 03-05-2026 |
| Dividend Yield | ★ 2.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.82 | N/A |
| Revenue Next Year | $15.80 | $677.91 |
| P/E Ratio | $53.06 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.98 | $1.33 |
| 52 Week High | $9.32 | $6.88 |
| Indicator | RPC | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 32.99 | 41.55 |
| Support Level | N/A | $4.86 |
| Resistance Level | $7.88 | $5.86 |
| Average True Range (ATR) | 0.29 | 0.29 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 1.50 | 36.26 |
Ridgepost Capital Inc, formelrly P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Its Revenue primarily comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.